Puglisi-Allegra S, Cabib S
Istituto di Psicobiologia e Psicofarmacologia, C.N.R., Roma, Italy.
Pharmacol Biochem Behav. 1988 Jul;30(3):765-8. doi: 10.1016/0091-3057(88)90096-2.
The dopamine agonist LY171555 (quinpirole), a specific D2 receptor agonist, induces catalepsy in mice at doses ranging from 0.3 to 10 mg/kg. The effects of an intermediate dose of this compound (1 mg/kg SC) were antagonized by 25 mg/kg of the selective D2 antagonist (-)-sulpiride (IP) injected 20 min before LY171555. SCH 23390, a selective D1 antagonist, administered (0.3 mg/kg IP) 20 min before LY171555 (1 mg/kg) enhanced the cataleptic effects of this compound. Finally, when the D1 dopamine receptor agonist SKF 38393 (20 mg/kg SC) was administered immediately beforehand, the cataleptic effects of 1 mg/kg of LY171555 were markedly reduced. These results suggest that there is a functional interaction between D1 and D2 dopamine receptors in the modulation of catalepsy.
多巴胺激动剂LY171555(喹吡罗)是一种特异性D2受体激动剂,在0.3至10毫克/千克的剂量范围内可诱导小鼠出现僵住症。在LY171555注射前20分钟注射25毫克/千克的选择性D2拮抗剂(-)-舒必利(腹腔注射)可拮抗该化合物中等剂量(1毫克/千克皮下注射)的作用。在LY171555(1毫克/千克)注射前20分钟给予选择性D1拮抗剂SCH 23390(0.3毫克/千克腹腔注射)可增强该化合物的僵住症作用。最后,若预先立即给予D1多巴胺受体激动剂SKF 38393(20毫克/千克皮下注射),1毫克/千克LY171555的僵住症作用会明显减弱。这些结果表明,在僵住症的调节过程中,D1和D2多巴胺受体之间存在功能相互作用。